Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna

Metagenomi Therapeutics, Inc.

2024-Q1 EPS reported -$1.19 revenue$11,159,000

Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.
Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.
Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.
R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.

Period: quarter ended March 31, 2024
Revenue: $11,159 thousand
Net income: Net loss of $(25,148) thousand
EPS: $(1.19) per share
Result: reported results

Exact text from the filing

announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.